Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3541860 · 2 trials · 2 indications
Cumulative number will be measured by magnetic resonance imaging (MRI) scans.
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3541860 Phase 2a Dose Level 1 | EXPERIMENTAL | LY3541860 will be given intravenously (IV) |
| LY3541860 Phase 2a Dose Level 2 | EXPERIMENTAL | LY3541860 will be given IV. |
| Placebo Phase 2a | PLACEBO_COMPARATOR | Placebo will be given IV. |
| LY3541860 Phase 2b Dose Level 3 | EXPERIMENTAL | LY3541860 will be given IV. |
| LY3541860 Phase 2b Dose Level 4 | EXPERIMENTAL | LY3541860 will be given IV. |
| Placebo Phase 2b | PLACEBO_COMPARATOR | Placebo will be given IV. |
| LY3541860 (Part A) | EXPERIMENTAL | Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC). |
| LY3541860 (Part B) | EXPERIMENTAL | Multiple doses of LY3541860 administered either IV or SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single doses of Placebo administered either IV or SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Multiple doses of Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3541860 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lu...
Top 20 of 21 competitors